Relmada Therapeutics plans a May 12, 2025 conference call to discuss Q1 financial results and business updates.
Quiver AI Summary
Relmada Therapeutics, Inc., a clinical-stage biotechnology company focused on innovative therapies, has announced a conference call and webcast scheduled for May 12, 2025, at 4:30 PM ET to discuss its financial results for Q1 2025 and recent business developments. Participants can join via specific dial-in numbers or access the webcast through the company's website. Relmada's lead program, NDV-01, is currently in a Phase 2 study for High-Grade Non-Muscle Invasive Bladder Cancer, and the company is also preparing to advance its investigational product sepranolone into further studies for compulsion-related disorders. Additional information can be found on Relmada's website.
Potential Positives
- Relmada Therapeutics is hosting a conference call and webcast to discuss financial results and recent business progress, indicating transparency and engagement with stakeholders.
- The company is advancing its lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, which demonstrates ongoing commitment to innovative cancer therapies.
- Preparations to advance sepranolone, a Phase 2b-ready product for compulsion-related disorders, highlight Relmada's focus on addressing unmet medical needs in behavioral health.
Potential Negatives
- Host of the conference call and webcast is solely focused on discussing financial results and recent business progress, indicating potential concerns regarding the company's current performance.
- The mention of a Phase 2 study for NDV-01 and preparations for further studies on sepranolone may imply that the company is still in the early stages of development, raising questions about its ability to bring products to market effectively.
- As a clinical-stage biotechnology company, Relmada faces the inherent risk of clinical trials failing or not achieving expected outcomes, which could negatively impact investor confidence and market performance.
FAQ
What is the date and time of Relmada's conference call?
The conference call is scheduled for May 12, 2025, at 4:30 PM ET.
How can I access the webcast for the conference call?
You can access the webcast by clicking the link provided in the press release or visiting Relmada's Investors section.
What will be discussed during the conference call?
The call will cover financial results for Q1 2025 and the company’s recent business progress.
What is Relmada Therapeutics known for?
Relmada is a clinical-stage biotechnology company focused on advancing innovative therapies for targeted patient populations.
How can I get in touch with Relmada for investor inquiries?
Investor inquiries can be directed to Brian Ritchie at LifeSci Advisors via email at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RLMD Hedge Fund Activity
We have seen 13 institutional investors add shares of $RLMD stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP removed 674,833 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $350,913
- MILLENNIUM MANAGEMENT LLC removed 561,826 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $292,149
- VESTAL POINT CAPITAL, LP removed 490,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $254,800
- OPALEYE MANAGEMENT INC. removed 480,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $249,600
- JPMORGAN CHASE & CO removed 277,359 shares (-88.0%) from their portfolio in Q4 2024, for an estimated $144,226
- PALO ALTO INVESTORS LP removed 237,254 shares (-32.4%) from their portfolio in Q4 2024, for an estimated $123,372
- SHAY CAPITAL LLC removed 175,547 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $91,284
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.
Conference Call and Webcast Information:
- Date: Monday, May 12, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Conference: 13753596
-
Webcast Access:
Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar .
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.
Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational product for compulsion-related disorders including Tourette’s Syndrome and Prader-Willi Syndrome, into further studies.
For more information, visit www.relmada.com . Follow us on LinkedIn.
Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]
Media Inquiries:
Corporate Communications
[email protected]
